What is the preferred influenza vaccine for an adult patient with a severe egg allergy, Flublok (recombinant influenza vaccine) or Fluzone (inactivated influenza vaccine)?

Flublok is Preferred for Severe Egg Allergy

For an adult patient with severe egg allergy, Flublok (recombinant influenza vaccine) is the preferred choice because it is manufactured completely without eggs and carries no contraindication for egg allergy of any severity. 1

Key Distinguishing Features

Manufacturing Process

• Flublok is produced using recombinant hemagglutinin (HA) technology in insect cell culture with a baculovirus vector, completely avoiding eggs in the manufacturing process 1
• Fluzone (standard inactivated influenza vaccine) is manufactured using embryonated chicken eggs and contains egg protein, making it contraindicated in patients with anaphylactic hypersensitivity to eggs 1

Egg Protein Content

• Flublok: Zero egg protein—manufactured without any egg exposure 1
• Fluzone: Contains measurable egg protein as it is egg-based 1

Clinical Recommendations by Allergy Severity

For Severe Egg Allergy (Beyond Hives)

• Flublok can be administered to persons with egg allergy of any severity who are aged 18 through 49 years without contraindication 1
• This is the safest option as it eliminates any theoretical risk of egg protein exposure 2

For Mild Egg Allergy (Hives Only)

• Either vaccine can be used without special precautions beyond standard vaccination protocols 2, 3
• However, if Flublok is available, it remains a reasonable choice to completely avoid egg exposure 2

Important Age Limitations

Critical caveat: The original Flublok formulation discussed in the 2013 ACIP guidelines was only approved for ages 18-49 years 1. Newer formulations (Flublok Quadrivalent) are approved for ages ≥18 years 2. If your patient falls outside this age range, alternative egg-free or low-egg options like cell-culture based vaccines (Flucelvax) should be considered 2.

Efficacy Considerations

Antigen Content

• Flublok contains 135 μg HA per dose (45 μg of each strain), which is three times more antigen than standard vaccines like Fluzone 1
• This higher antigen content results in improved immunogenicity 4, 5

Clinical Effectiveness

• In adults aged 50-64 years, recombinant vaccine (Flublok) demonstrated 15.3% greater relative vaccine effectiveness against PCR-confirmed influenza compared to standard-dose vaccines (95% CI: 5.9-23.8%, P=0.002) 6
• The 2007-08 efficacy study showed 75.4% vaccine effectiveness against matched strains, though interpretation was limited by antigenic mismatch 1

Safety Profile

• Most common adverse reactions with Flublok include injection site pain (>37%), headache (>15%), fatigue (>15%), and myalgias (>11%) 1
• Local pain and tenderness occur more frequently than with standard vaccines, but 94% of pain reports were rated as mild 1
• No serious vaccine-related adverse events related to egg allergy have been reported 4

Practical Algorithm

1. Confirm severe egg allergy (reactions beyond hives: angioedema, respiratory distress, recurrent emesis, or requiring epinephrine) 3
2. Verify patient age is within approved range (≥18 years for current formulations) 2
3. Administer Flublok as the preferred egg-free option 1
4. If Flublok unavailable: Standard vaccines can still be used but must be administered in a medical setting with supervision by providers capable of recognizing and managing severe allergic reactions 2, 3

Common Pitfalls to Avoid

• Do not delay vaccination waiting for Flublok if it's unavailable—even egg-based vaccines can be safely administered in appropriate medical settings for severe egg allergy 1
• Do not perform skin testing before vaccination—this is no longer recommended 3
• Do not use divided-dose protocols—these are outdated 3
• Ensure vaccination occurs where personnel and equipment for managing anaphylaxis are available, as with all vaccines 2